Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 11/2014

01-11-2014 | Original Article

89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer

Authors: Neeta Pandit-Taskar, Joseph A. O’Donoghue, Volkan Beylergil, Serge Lyashchenko, Shutian Ruan, Stephen B. Solomon, Jeremy C. Durack, Jorge A. Carrasquillo, Robert A. Lefkowitz, Mithat Gonen, Jason S. Lewis, Jason P. Holland, Sarah M. Cheal, Victor E. Reuter, Joseph R. Osborne, Massimo F. Loda, Peter M. Smith-Jones, Wolfgang A. Weber, Neil H. Bander, Howard I. Scher, Michael J. Morris, Steven M. Larson

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2014

Login to get access

Abstract

Purpose

Given the bone tropism of prostate cancer, conventional imaging modalities poorly identify or quantify metastatic disease. 89Zr-huJ591 positron emission tomography (PET) imaging was performed in patients with metastatic prostate cancer to analyze and validate this as an imaging biomarker for metastatic disease. The purpose of this initial study was to assess safety, biodistribution, normal organ dosimetry, and optimal imaging time post-injection for lesion detection.

Methods

Ten patients with metastatic prostate cancer received 5 mCi of 89Zr-huJ591. Four whole-body scans with multiple whole-body count rate measurements and serum activity concentration measurements were obtained in all patients. Biodistribution, clearance, and lesion uptake by 89Zr-huJ591 immuno-PET imaging was analyzed and dosimetry was estimated using MIRD techniques. Initial assessment of lesion targeting of 89Zr-huJ591 was done. Optimal time for imaging post-injection was determined.

Results

The dose was well tolerated with mild chills and rigors seen in two patients. The clearance of 89Zr-huJ591 from serum was bi-exponential with biological half-lives of 7 ± 4.5 h (range 1.1–14 h) and 62 ± 13 h (range 51–89 h) for initial rapid and later slow phase. Whole-body biological clearance was 219 ± 48 h (range 153–317 h). The mean whole-body and liver residence time was 78.7 and 25.6 h, respectively. Dosimetric estimates to critical organs included liver 7.7 ± 1.5 cGy/mCi, renal cortex 3.5 ± 0.4 cGy/mCi, and bone marrow 1.2 ± 0.2 cGy/mCi. Optimal time for patient imaging after injection was 7 ± 1 days. Lesion targeting of bone or soft tissue was seen in all patients. Biopsies were performed in 8 patients for a total 12 lesions, all of which were histologically confirmed as metastatic prostate cancer. One biopsy-proven lesion was not positive on 89Zr-huJ591, while the remaining 11 lesions were 89Zr-huJ591 positive. Two biopsy-positive nodal lesions were noted only on 89Zr-huJ591 study, while the conventional imaging modality was negative.

Conclusion

89Zr-huJ591 PET imaging of prostate-specific membrane antigen expression is safe and shows good localization of disease in prostate cancer patients. Liver is the critical organ for dosimetry, and 7 ± 1 days is the optimal imaging time. A larger study is underway to determine lesion detection in an expanded cohort of patients with metastatic prostate cancer.
Literature
1.
2.
Morris MJ, Autio KA, Basch EM, Danila DC, Larson S, Scher HI. Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable? Semin Oncol 2013;40(3):375–92.PubMedCrossRef
3.
Haseebuddin M, Dehdashti F, Siegel BA, Liu J, Roth EB, Nepple KG, et al. 11C-acetate PET/CT before radical prostatectomy: nodal staging and treatment failure prediction. J Nucl Med 2013;54(5):699–706.PubMedCrossRefPubMedCentral
4.
Schuster DM, Nieh PT, Jani AB, Amzat R, Bowman FD, Halkar RK, et al. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. J Urol 2014;191(5):1446–53.PubMedCrossRefPubMedCentral
5.
Schroeder RP, van Weerden WM, Krenning EP, Bangma CH, Bemdsen S, Grievink-de Ligt CH, et al. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Eur J Nucl Med Mol Imaging 2011;38(7):1257–66.PubMedCrossRefPubMedCentral
6.
Nanda PK, Pandey U, Bottenus BN, Rold TL, Sieckman GL, Szczodroski AF, et al. Bombesin analogues for gastrin-releasing peptide receptor imaging. Nucl Med Biol 2012;39(4):461–71.PubMedCrossRef
7.
8.
Carlucci G, Ananias HJ, Yu Z, Hoving HD, Helfrich W, Diercks RA, et al. Preclinical evaluation of a novel (111)In-labeled bombesin homodimer for improved imaging of GRPR-positive prostate cancer. Mol Pharm 2013;10(5):1716–24.PubMedCrossRef
9.
Pan D, Xu YP, Yang RH, Wang L, Chen F, Luo S, et al. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging. Amino Acids 2014;46:1481–9.
10.
Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998;83(11):2259–69.PubMedCrossRef
11.
Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998;82(11):2256–61.PubMedCrossRef
12.
Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Mühlmann G, et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol 2009;40(12):1754–61.PubMedCrossRef
13.
Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003;170(5):1717–21.PubMedCrossRef
14.
Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003;30(5):667–77.PubMedCrossRef
15.
Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998;58(18):4055–60.PubMed
16.
Pandit-Taskar N, O’Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, et al. Antibody mass escalation study in patients with castration-resistant prostate cancer using (111)In-J591: lesion detectability and dosimetric projections for (90)Y radioimmunotherapy. J Nucl Med 2008;49(7):1066–74.PubMedCrossRefPubMedCentral
17.
Morris MJ, Pandit-Taskar N, Divgi CR, Bender S, O’Donoghue JA, Nacca A, et al. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res 2007;13(9):2707–13.PubMedCrossRef
18.
Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, et al. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res 2005;11(20):7454–61.PubMedCrossRef
19.
Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22(13):2522–31.PubMedCrossRef
20.
Trabulsi EJ, Yao D, Joyce MA, et al. Phase I radioimmunotherapy (RIT) trials of monoclonal antibody (mAb) J591 to the extracellular domain of prostate specific membrane antigen (PSMA(ext)) radiolabeled with (90)yttrium (Y-90) or (177)lutetium (Lu-177) in advanced prostate cancer (Pca). J Urol 2003;169(4):396–7.
21.
Nanus DM, Milowsky MI, Kostakoglu L, Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003;170(6):S84–8.PubMedCrossRef
22.
23.
Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc 2010;5(4):739–43.PubMedCrossRef
24.
Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 2010;51(8):1293–300.PubMedCrossRefPubMedCentral
25.
Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn Jr PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72(1):77–89.PubMedCrossRef
26.
Morris MJ, Pandit-Taskar N, Carrasquillo JA, O’Donoghue JA, Humm J, Serge K, et al. Phase I trial of zirconium 89 (Zr89) radiolabeled J591 in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2013;31(Suppl 6; abstract 31).
27.
Pandit-Taskar N, O’Donoghue J, et al. 89Zr J591 immunoPET imaging in patients with prostate cancer. J Nucl Med 2013;54(Suppl 2):287.
28.
Lutje S, Boerman OC, van Rij CM, Sedelaar M, Helfrich W, Oyen WJ, et al. Prospects in radionuclide imaging of prostate cancer. Prostate 2012;72(11):1262–72.PubMedCrossRef
29.
Yu Z, Carlucci G, Ananias HJ, Dierckx RA, Liu S, Helfrich W, et al. Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer. Amino Acids 2013;44(2):543–53.PubMedCrossRef
30.
Castellucci P, Picchio M. 11C-choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging 2013;40 Suppl 1:S36–40.PubMedCrossRef
31.
Ceci F, Castellucci P, Mamede M, Schiavina R, Rubello D, Fuccio C, et al. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. Eur J Nucl Med Mol Imaging 2013;40(2):149–55.PubMedCrossRef
32.
Ceci F, Schiavina R, Castellucci P, Brunocilla E, Fuccio C, Colletti PM, et al. 11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study. Clin Nucl Med 2013;38(7):e279–82.PubMedCrossRef
33.
Nanni C, Schiavina R, Brunocilla E, Borghesi M, Ambrosini V, Zanoni L, et al. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clin Genitourin Cancer 2014;12(2):106–10.PubMedCrossRef
34.
Turkbey B, Mena E, Shih J, Pinto PA, Merino MJ, Lindenberg ML, et al. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. Radiology 2014;270(3):849–56.PubMedCrossRef
35.
Nye JA, Schuster DM, Yu W, Camp VM, Goodman MM, Votaw JR. Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. J Nucl Med 2007;48(6):1017–20.PubMedCrossRef
36.
Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, et al. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J Nucl Med 2012;53(12):1883–91.PubMedCrossRefPubMedCentral
37.
Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, et al. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist–from mice to men. Theranostics 2014;4(4):412–9.PubMedCrossRefPubMedCentral
38.
Dijkgraaf I, Franssen GM, McBride WJ, D’Souza CA, Laverman P, Smith CJ, et al. PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog. J Nucl Med 2012;53(6):947–52.PubMedCrossRef
39.
Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F, Nicolas G, et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med 2011;52(12):1970–8.PubMedCrossRef
40.
Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2014;41(1):11–20.PubMedCrossRefPubMedCentral
41.
Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a (124)I/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 2014;41:1280–92.
42.
Hillier SM, Kern AM, Maresca KP, Marquis JC, Eckelman WC, Joyal JL, et al. 123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. J Nucl Med 2011;52(7):1087–93.PubMedCrossRef
43.
Barrett JA, Coleman RE, Goldsmith SJ, Vallabhajosula S, Petry NA, Cho S, et al. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med 2013;54(3):380–7.PubMedCrossRef
44.
Barrett PH, Bell BM, Cobelli C, Golde H, Schumitzky A, Vicini P, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism 1998;47(4):484–92.PubMedCrossRef
45.
Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46(6):1023–7.PubMed
46.
Sgouros G, Stabin M, Erdi Y, Akabani G, Kwok C, Brill AB, et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys 2000;27(9):2150–64.PubMedCrossRef
Metadata
Title
89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer
Authors
Neeta Pandit-Taskar
Joseph A. O’Donoghue
Volkan Beylergil
Serge Lyashchenko
Shutian Ruan
Stephen B. Solomon
Jeremy C. Durack
Jorge A. Carrasquillo
Robert A. Lefkowitz
Mithat Gonen
Jason S. Lewis
Jason P. Holland
Sarah M. Cheal
Victor E. Reuter
Joseph R. Osborne
Massimo F. Loda
Peter M. Smith-Jones
Wolfgang A. Weber
Neil H. Bander
Howard I. Scher
Michael J. Morris
Steven M. Larson
Publication date
01-11-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-014-2830-7

Other articles of this Issue 11/2014

European Journal of Nuclear Medicine and Molecular Imaging 11/2014 Go to the issue

Original Article

Impact of 18F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients

Original Article

Furosemide diminishes 18F-fluoroethylcholine uptake in prostate cancer in vivo

Editorial

Molecular imaging: the emerging role of optical imaging in nuclear medicine

Editorial

Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging

UEMS/EBNM

Ideas from the second UEMS conference on CME/CPD: new EU directives on a patients’ rights in cross-border healthcare and professional qualifications

Original Article

213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience